290 related articles for article (PubMed ID: 12835221)
1. Prognostic impact of vascular leakage in acute Kawasaki disease.
Terai M; Honda T; Yasukawa K; Higashi K; Hamada H; Kohno Y
Circulation; 2003 Jul; 108(3):325-30. PubMed ID: 12835221
[TBL] [Abstract][Full Text] [Related]
2. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
[TBL] [Abstract][Full Text] [Related]
3. Increased serum levels of vascular endothelial growth factor in Kawasaki disease.
Maeno N; Takei S; Masuda K; Akaike H; Matsuo K; Kitajima I; Maruyama I; Miyata K
Pediatr Res; 1998 Oct; 44(4):596-9. PubMed ID: 9773852
[TBL] [Abstract][Full Text] [Related]
4. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
5. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
6. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis.
Tamura M; Ohta Y
Cancer; 2003 Sep; 98(6):1217-22. PubMed ID: 12973845
[TBL] [Abstract][Full Text] [Related]
7. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.
Muta H; Ishii M; Egami K; Furui J; Sugahara Y; Akagi T; Nakamura Y; Yanagawa H; Matsuishi T
J Pediatr; 2004 Apr; 144(4):496-9. PubMed ID: 15069399
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor in acute Kawasaki disease.
Terai M; Yasukawa K; Narumoto S; Tateno S; Oana S; Kohno Y
Am J Cardiol; 1999 Feb; 83(3):337-9. PubMed ID: 10072219
[TBL] [Abstract][Full Text] [Related]
9. Neutrophils and mononuclear cells express vascular endothelial growth factor in acute Kawasaki disease: its possible role in progression of coronary artery lesions.
Hamamichi Y; Ichida F; Yu X; Hirono KI; Uese KI; Hashimoto I; Tsubata S; Yoshida T; Futatani T; Kanegane H; Miyawaki T
Pediatr Res; 2001 Jan; 49(1):74-80. PubMed ID: 11134495
[TBL] [Abstract][Full Text] [Related]
10. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.
Sittiwangkul R; Pongprot Y; Silvilairat S; Phornphutkul C
Singapore Med J; 2006 Sep; 47(9):780-4. PubMed ID: 16924360
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
12. Infections and Kawasaki disease: implications for coronary artery outcome.
Benseler SM; McCrindle BW; Silverman ED; Tyrrell PN; Wong J; Yeung RS
Pediatrics; 2005 Dec; 116(6):e760-6. PubMed ID: 16322132
[TBL] [Abstract][Full Text] [Related]
13. Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease.
Hirono K; Foell D; Xing Y; Miyagawa-Tomita S; Ye F; Ahlmann M; Vogl T; Futatani T; Rui C; Yu X; Watanabe K; Wanatabe S; Tsubata S; Uese K; Hashimoto I; Ichida F; Nakazawa M; Roth J; Miyawaki T
J Am Coll Cardiol; 2006 Sep; 48(6):1257-64. PubMed ID: 16979015
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
Simonini G; Masi L; Giani T; Piscitelli E; Cimaz R; Vierucci S; Brandi ML; Falcini F
J Rheumatol; 2005 Nov; 32(11):2233-8. PubMed ID: 16265708
[TBL] [Abstract][Full Text] [Related]
15. Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease.
Yasukawa K; Terai M; Shulman ST; Toyozaki T; Yajima S; Kohno Y; Rowley AH
Circulation; 2002 Feb; 105(6):766-9. PubMed ID: 11839635
[TBL] [Abstract][Full Text] [Related]
16. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis, treatment and outcome of Kawasaki disease in an Australian tertiary setting: a review of three years experience.
Singh-Grewal D; Wong M; Isaacs D
J Paediatr Child Health; 2005; 41(9-10):495-9. PubMed ID: 16150066
[TBL] [Abstract][Full Text] [Related]
18. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[TBL] [Abstract][Full Text] [Related]
19. Platelet vascular endothelial growth factor is a useful predictor for prognosis in Kawasaki syndrome.
Ueno K; Nomura Y; Hashiguchi T; Masuda K; Morita Y; Hazeki D; Eguchi T; Maruyama I; Kawano Y
Br J Haematol; 2010 Jan; 148(2):285-92. PubMed ID: 19793253
[TBL] [Abstract][Full Text] [Related]
20. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC; Yang KD; Liang CD; Bong CN; Yu HR; Wang L; Wang CL
Pediatr Allergy Immunol; 2007 Jun; 18(4):354-9. PubMed ID: 17584314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
